Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).

NCT00588835 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT00588835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00588835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2008
Completion date
January 31, 2010
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tumor